Senti Biosciences Holdings (SNTI) Asset Writedowns and Impairment (2023 - 2025)

Senti Biosciences Holdings' Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $5.1 million for Q4 2025.

• In Q4 2025, Asset Writedowns and Impairment rose 1600.0% year-over-year to $5.1 million; the TTM figure through Dec 2025 stood at $5.7 million (down 78.43% YoY), while the FY2025 annual figure was $5.1 million, up 1600.0% from the prior year.
• Asset Writedowns and Impairment for Q4 2025 stood at $5.1 million, up from $300000.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $25.7 million in Q3 2023, with the low at $262000.0 in Q4 2023.
• The 3-year median for Asset Writedowns and Impairment is $2.7 million (2024), against an average of $7.8 million.
• The sharpest annual moves came in 2024 and 2025: Asset Writedowns and Impairment advanced 14.5% in 2024, then soared 1600.0% in 2025.
• Senti Biosciences Holdings' Asset Writedowns and Impairment stood at $262000.0 in 2023, then climbed by 14.5% to $300000.0 in 2024, then jumped by 1600.0% to $5.1 million in 2025.
• Business Quant data shows SNTI's Asset Writedowns and Impairment at $5.1 million in Q4 2025, $300000.0 in Q4 2024, and $262000.0 in Q4 2023.